Literature DB >> 1633072

Update on nitrate tolerance.

J O Parker1.   

Abstract

1. It is now recognised that nitrate therapy designed to provide effects throughout 24 h each day induces tolerance. Such tolerance may be partial or complete and is associated with diminished haemodynamic and clinical effects. 2. The mechanism of tolerance is not completely understood but it seems to be related to the depletion of reduced sulphydryl groups in vascular smooth muscle and to the activation of counter-regulatory forces. These include elevated plasma catecholamines, arginine vasopressin and plasma renin activity. Activity of the renin-angiotensin system is associated with sodium and water retention and plasma volume expansion. The increase in vasoconstrictor influences and augmented plasma volume could modulate the effect of nitrate-induced vasodilatation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633072      PMCID: PMC1381216          DOI: 10.1111/j.1365-2125.1992.tb04142.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin.

Authors:  J D Parker; B Farrell; T Fenton; M Cohanim; J O Parker
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

2.  Effect of intervals between doses on the development of tolerance to isosorbide dinitrate.

Authors:  J O Parker; B Farrell; K A Lahey; G Moe
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

3.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.

Authors:  L J Ignarro; H Lippton; J C Edwards; W H Baricos; A L Hyman; P J Kadowitz; C A Gruetter
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

4.  Prevention and reversal of nitrate tolerance in patients with congestive heart failure.

Authors:  M Packer; W H Lee; P D Kessler; S S Gottlieb; N Medina; M Yushak
Journal:  N Engl J Med       Date:  1987-09-24       Impact factor: 91.245

5.  The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate.

Authors:  M M Bassan
Journal:  J Am Coll Cardiol       Date:  1990-10       Impact factor: 24.094

6.  Different sensitivities of arteries and veins to glyceryltrinitrate-induced relaxation and tolerance: an "in vitro" study on isolated vessels from rabbits.

Authors:  R Rösen; E König; W Klaus
Journal:  Arch Int Pharmacodyn Ther       Date:  1987-02

7.  Failure of transdermal nitroglycerin to improve chronic stable angina: a randomized, placebo-controlled, double-blind, double crossover trial.

Authors:  P A Crean; P Ribeiro; F Crea; G J Davies; D Ratcliffe; A Maseri
Journal:  Am Heart J       Date:  1984-12       Impact factor: 4.749

8.  Nitrate tolerance: the lack of effect of N-acetylcysteine.

Authors:  J O Parker; B Farrell; K A Lahey; B F Rose
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

9.  Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina.

Authors:  H DeMots; S P Glasser
Journal:  J Am Coll Cardiol       Date:  1989-03-15       Impact factor: 24.094

10.  Sustained effects of transdermal nitroglycerin in patients with angina pectoris.

Authors:  A S Kapoor; N S Dang; R D Reynolds
Journal:  Clin Ther       Date:  1985       Impact factor: 3.393

View more
  2 in total

1.  Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure.

Authors:  J A Bauer; J P Balthasar; H L Fung
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

2.  Effects of nifedipine, metronidazole, and nitric oxide donors on spore germination and cell culture infection of the microsporidia Encephalitozoon hellem and Encephalitozoon intestinalis.

Authors:  Q He; G J Leitch; G S Visvesvara; S Wallace
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.